Document is current
Any future updates will be listed below
-
Authors
Garsed, Dale W. https://orcid.org/0000-0003-1223-0121
Pandey, Ahwan https://orcid.org/0000-0003-2238-1054
Fereday, Sian https://orcid.org/0000-0002-8559-8579
Kennedy, Catherine J. https://orcid.org/0000-0002-4465-5784
Takahashi, Kazuaki
Alsop, Kathryn
Hamilton, Phineas T.
Hendley, Joy
Chiew, Yoke-Eng
Traficante, Nadia
Provan, Pamela https://orcid.org/0000-0001-8346-2603
Ariyaratne, Dinuka https://orcid.org/0000-0001-5704-9030
Au-Yeung, George
Bateman, Nicholas W. https://orcid.org/0000-0002-4425-9511
Bowes, Leanne
Brand, Alison
Christie, Elizabeth L. https://orcid.org/0000-0002-9959-7024
Cunningham, Julie M. https://orcid.org/0000-0002-8159-3025
Friedlander, Michael
Grout, Bronwyn
Harnett, Paul
Hung, Jillian
McCauley, Bryan
McNally, Orla
Piskorz, Anna M.
Saner, Flurina A. M. https://orcid.org/0000-0003-2469-9824
Vierkant, Robert A. https://orcid.org/0000-0001-6242-5221
Wang, Chen https://orcid.org/0000-0003-2638-3081
Winham, Stacey J. https://orcid.org/0000-0002-8492-9102
Pharoah, Paul D. P. https://orcid.org/0000-0001-8494-732X
Brenton, James D. https://orcid.org/0000-0002-5738-6683
Conrads, Thomas P. https://orcid.org/0000-0003-4742-3281
Maxwell, George L.
Ramus, Susan J. https://orcid.org/0000-0003-0005-7798
Pearce, Celeste Leigh
Pike, Malcolm C.
Nelson, Brad H. https://orcid.org/0000-0002-4445-5539
Goode, Ellen L.
DeFazio, Anna https://orcid.org/0000-0003-0057-4744
Bowtell, David D. L. https://orcid.org/0000-0001-9089-7525
- License Information
-
More Information
Article History
Received: 6 January 2022
Accepted: 17 October 2022
First Online: 1 December 2022
Competing interests
: S.F., K.A., N.T. and A.D. received grant funding from AstraZeneca for unrelated work. G.A.-Y. received grant funding from AstraZeneca and Roche-Genentech for unrelated work. M.F. declares honoraria for advisory boards AstraZeneca, GSK, Incyclix, Lilly, MSD, Novartis and Takeda; consultancy for AstraZeneca, Eisai and Novartis; speaker’s fee and travel from AstraZeneca; speaker’s fee from ACT Genomics; and institutional research funding from AstraZeneca, BeiGene, Novartis; all for unrelated work. J.D.B. received funding from Aprea and Clovis Oncology for unrelated work. D.D.L.B. received funding from AstraZeneca, Genentech-Roche and BeiGene for unrelated work. The remaining authors declare no competing interests.
